Detalhe da pesquisa
1.
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Cancer
; 130(2): 287-299, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37801052
2.
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Blood
; 138(21): 2042-2050, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407543
3.
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
Ann Hematol
; 102(6): 1375-1382, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37079069
4.
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.
Int J Mol Sci
; 25(1)2023 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38203288
5.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636033
6.
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Blood
; 135(8): 534-541, 2020 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31877211
7.
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
Haematologica
; 107(10): 2356-2364, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385922
8.
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Am J Hematol
; 97(11): 1419-1426, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054756
9.
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Acta Oncol
; 60(11): 1527-1533, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499575
10.
Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.
Qual Life Res
; 29(3): 815-823, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31782016
11.
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Haematologica
; 104(8): 1589-1596, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30819917
12.
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Ann Hematol
; 98(10): 2329-2338, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392461
13.
Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies.
Value Health
; 22(11): 1303-1310, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31708068
14.
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
Cancer
; 124(10): 2228-2237, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29499087
15.
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
Ann Hematol
; 97(1): 95-100, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28971265
16.
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.
J Cell Biochem
; 118(11): 3968-3975, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28401599
17.
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.
Haematologica
; 102(9): 1530-1536, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28572163
18.
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.
Ann Hematol
; 96(4): 549-558, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27686083
19.
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Am J Hematol
; 92(1): 82-87, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27770583
20.
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Am J Hematol
; 92(8): 797-805, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466557